Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)
Company Research
Source: GlobeNewswire
ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan diseases, today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome. This new product combines a broad spectrum serine protease inhibitor with an anti-inflammatory agent in a proprietary topical formulation. Quoin anticipates that patents arising from these applications will extend to at least 2044. “As we continue to advance the clinical development of Quoin’s lead asset for Netherton Syndrome, we are pursuing opportunities to strengthen our industry-leading position in this disease space. Today’s announcement further underscores our commitment to innovation and to the expansion of our intellectual property portfolio. This n
Show less
Read more
Impact Snapshot
Event Time:
QNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNRX alerts
High impacting Quoin Pharmaceuticals, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
QNRX
News
- Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 [Yahoo! Finance]Yahoo! Finance
- Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024GlobeNewswire
- Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) had its price target lowered by analysts at Maxim Group from $15.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
QNRX
Analyst Actions
- 3/15/24 - Maxim Group
QNRX
Sec Filings
- 5/3/24 - Form 8-K
- 4/9/24 - Form 8-K
- 4/4/24 - Form EFFECT
- QNRX's page on the SEC website